Listed pharma companies’ profits rise 11pc in 1QFY27

Pakistan’s listed drugmakers earned Rs11.6 billion in 1QFY27, an 11 percent increase from a year earlier and 54 percent above the preceding quarter, Business Recorder reported, citing Topline Research. Revenue reached Rs98.8 billion, rising 5 percent year on year as prices and volumes supported sales. The report noted that this growth came despite the absence of Afghanistan exports, which had featured in the comparison period.

The sector’s market value fell to Rs505.2 billion, down 24 percent year on year, even as gross margin advanced to 43.7 percent from 41.9 percent. AGP posted a 64.6 percent gross margin; SEARL and HINOON followed at 57.2 percent and 57.1 percent. Finance expenses climbed 22 percent year on year to Rs1.1 billion, while the tax bill was Rs7.1 billion. Analysts expect volumes to benefit from new products, seasonal winter demand and a low comparison base.